Which assay broadly screens for fungal infections but may yield false positives and negatives?

Which assay broadly screens for fungal infections but may yield false positives and negatives?

• A. Beta-D-glucan (BDG) assay
• B. Galactomannan enzyme immunoassay
• C. KOH direct prep
• D. Fungal culture

Answer: (A)

Beta-D-glucan in serum acts as a broad screen for invasive fungal infections because it detects a component found in many fungal cell walls, so a positive result suggests a fungal process and helps raise suspicion in high-risk patients. The strength of this test is its wide reach: it can pick up infections from several common fungi, not just one species, which makes it a useful first step when invasive fungal disease is in the differential. But because it is not organism-specific, results must be interpreted with context. A true positive can occur in a range of fungal infections, but the test is prone to false positives as well, coming from glucan-containing substances and materials encountered in medical care—some IV products, hemodialysis filters, gauze, and other equipment can introduce glucan into the bloodstream. Conversely, some fungi carry little or no detectable BDG in their cell walls, and infections caused by those organisms may yield false negatives. Early infections or low fungal burden, or prior antifungal therapy, can also reduce BDG levels and mask disease. In practice, BDG is a helpful initial screening tool to prompt further diagnostic workup—culture, histopathology, imaging, and other specific tests—rather than a definitive diagnosis on its own.

Beta-D-glucan in serum acts as a broad screen for invasive fungal infections because it detects a component found in many fungal cell walls, so a positive result suggests a fungal process and helps raise suspicion in high-risk patients. The strength of this test is its wide reach: it can pick up infections from several common fungi, not just one species, which makes it a useful first step when invasive fungal disease is in the differential.

But because it is not organism-specific, results must be interpreted with context. A true positive can occur in a range of fungal infections, but the test is prone to false positives as well, coming from glucan-containing substances and materials encountered in medical care—some IV products, hemodialysis filters, gauze, and other equipment can introduce glucan into the bloodstream. Conversely, some fungi carry little or no detectable BDG in their cell walls, and infections caused by those organisms may yield false negatives. Early infections or low fungal burden, or prior antifungal therapy, can also reduce BDG levels and mask disease.

In practice, BDG is a helpful initial screening tool to prompt further diagnostic workup—culture, histopathology, imaging, and other specific tests—rather than a definitive diagnosis on its own.